RxDoctor Payments Data

John Ekman

Psychiatric/Mental Health · Tucson, AZNPI 1194722256

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $10,177 of the $13,148 with a category attached, or 77.4%. AbbVie accounts for 61.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $8,228 and has fallen 98.4% since, to $134 in 2025. Among psychiatric/mental health clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$13,148in general payments, 2019–2025

Across 41 payments — averaging $320.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • Otsuka America Pharmaceutical, Inc.$5K
  • Teva Pharmaceuticals USA, Inc.$111
  • Alkermes, Inc.$53
  • E.r. Squibb & Sons, L.L.C.$23

What the payments were for

  • Speaking & faculty fees$10,17777%
  • Travel & lodging$2,12116%
  • Food & beverage$7396%
  • Education$1111%

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,148 in reported general payments places this provider in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.

See all psychiatric/mental health providers in Arizona

Medicare billing

Part B allowed, 2024
$16,098
Medicare patients
49
Services billed
170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate40$129,128
Abilify MaintenaAripiprazole24$68,980
Seroquel XrQuetiapine Fumarate15$22,701
Aripiprazole97$10,324
Methylphenidate ErMethylphenidate Hcl12$5,600
Chlorpromazine Hcl35$5,050
Lurasidone Hcl23$5,037
Clozapine50$4,073
Prochlorperazine Maleate168$3,988
Quetiapine Fumarate165$2,962
Duloxetine Hcl156$2,756
Quetiapine Fumarate ErQuetiapine Fumarate46$2,347
Ziprasidone Hcl60$2,106
Divalproex Sodium ErDivalproex Sodium50$2,083
Olanzapine OdtOlanzapine19$1,930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$4,908$68,98024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.

Other psychiatric/mental health in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →